Browse MAGEA3

Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF01454 MAGE family
PF12440 Melanoma associated antigen family N terminal
Function

Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

> Gene Ontology
 
Biological Process GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0010955 negative regulation of protein processing
GO:0016485 protein processing
GO:0034976 response to endoplasmic reticulum stress
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045861 negative regulation of proteolysis
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
GO:0070613 regulation of protein processing
GO:0097193 intrinsic apoptotic signaling pathway
GO:1902235 regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway
GO:1902236 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:1903573 negative regulation of response to endoplasmic reticulum stress
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0002020 protease binding
GO:0089720 caspase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAGEA3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MAGEA3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24671426MelanomaPromote immunity (T cell function); essential for immunotherapyMAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine. To determine whether generating melanoma antigen family A, 3 (MAGE-A3), a tumor-specific cancer-testis antigen, as a fusion protein with CPD will enhance the cytosolic bioavailability of MAGE-A3. Enhanced cytosolic bioavailability of tumor-specific antigens improves access to human leukocyte antigen (HLA) class I molecules for more efficient cytotoxic T lymphocyte generation.
24520093Plasma Cell MyelomaPromote immunity (T/NK cell function); essential for immunotherapyCombination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. A high frequency of vaccine-specific T-cell responses were generated after transplant by combining costimulated autologous T cells with a Poly-ICLC/GM-CSF-primed MAGE-A3 vaccine.
23838315Childhood acute lymphoblastic leukemiaPromote immunity (T cell function); essential for immunotherapyPeripheral blood mononuclear cells were stimulated with autologous dendritic cells pulsed with complete peptide libraries of WT1, Survivin, MAGE-A3, and PRAME, antigens frequently expressed on ALL blasts. Antigen-specificity was observed in more than 50% of patients after the initial stimulation and increased to more than 90% after three stimulations as assessed in IFN-γ-enzyme-linked immunospot (ELISpot) and (51)Cr-release assays. This study supports the use of immunotherapy with adoptively transferred autologous tumor antigen-specific T cells to prevent relapse and improve the prognosis of patients with high-risk ALL.
19074732MelanomaPromote immunity (T cell function)Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination.
29674449lung carcinomaPromote immunityThe ihv-DCs, which are engineered to express MAGEA3 and high levels of 4-1BBL and MICA, induce simultaneous production of both HLA-A2-restricted, MAGEA3-specific CTLs and NK cells from HLA-A2+ donor peripheral blood mononuclear cells.
23904461MelanomaPromote immunity (T cell function); essential for immunotherapyAutologous monocyte-derived dendritic cells (DCs) electroporated with synthetic messenger RNA (mRNA) encoding a CD40 ligand, a constitutively active Toll-like receptor 4 and CD70, together with mRNA encoding fusion proteins of a human leukocyte antigen (HLA)-class II targeting signal (DC-LAMP) and a melanoma-associated antigen (MAA); either MAGE-A3, MAGE-C2, tyrosinase or gp100) (TriMixDC-MEL) are superiorly immunogenic.
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAGEA3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAGEA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6880.309
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5120.809
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.5930.425
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5930.3
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7730.395
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3450.563
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.6150.69
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.1640.329
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.9090.37
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682301.2510.0433
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAGEA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAGEA3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAGEA3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAGEA3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAGEA3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAGEA3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAGEA3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAGEA3
Namemelanoma antigen family A3
Aliases HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAGEA3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.